# Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

> **NCT02935361** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Southern California** · enrollment: 33 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Guadecitabine

## Key facts

- **NCT ID:** NCT02935361
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935361, "Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02935361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*